<DOC>
	<DOC>NCT01019863</DOC>
	<brief_summary>Evaluation of the efficacy, tolerance, quality of life and cost effectiveness of the association of Oxaliplatin, Gemcitabine, Rituximab and Dexamethasone for treatment of patients with refractory or relapsing non-Hodgkin lymphoma.</brief_summary>
	<brief_title>Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1. Patients 18 years or above at the time of inclusion. 2. Documented CD20+ NHL, refractory or relapsing after first line chemotherapy. 3. No contraindication to Oxaliplatin, Gemcitabine, Dexamethasone or Rituximab. 1. Other types of nonHodgkin lymphoma 2. Pregnancy and lactation. 3. Patient unable to give written informed consent. 4. Contraindication ou intolerance to any of the components of the RGDOx chemotherapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>